| Revenue growth | FY26 Revenue: INR 647.6 mn (down 7.6% YoY) |
|---|---|
| Margins | EBITDA down 8.1% in FY26; Q4 EBITDA down 45.6% |
| Demand visibility | Strong export focus (~75% revenue share) |
Growth
Q4 revenue down 42.2%, PAT down 57.2% YoY. FY26 revenue fell 7.6%, PAT dropped 14.6% YoY.
Outlook
Ongoing expansion with new plants in Prague and Pune (2025). Expanding into high-margin IV infusions.
Risks
Substantial year-on-year declines in revenue and profitability across all primary standalone metrics during FY26.
Earnings Call filed with BSE, NSE: SANJIVIN. Summary written with AI assistance from the document.
Sanjivani Paranteral Ltd: key numbers
- Share price
- ₹175.05
- Market cap
- ₹215.0 Cr
- Revenue (annual)
- ₹68.67 Cr
- Net profit (annual)
- ₹6.79 Cr
- P/E (TTM)
- 20.4×Sector 47.4×
- Promoter holding
- 31.56%+0.30% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sanjivani Paranteral Ltd
All →Sanjivani Paranteral Fund Raise
Sanjivani Paranteral clarified the objects of its proposed 5 lakh convertible warrant issue to BSE. Proceeds of ~₹5.80 Cr will fund capex and subsidiary working capital for expansion.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral Limited held its 32nd Annual General Meeting on September 16, 2026. The meeting concluded with resolutions on financial statements and director re-appointment.
Sanjivani Paranteral Annual Report
Sanjivani Paranteral Limited has filed its Annual Report for the financial year 2025-26 as required under SEBI regulations. The document details the company's annual performance.
Sanjivani Paranteral Annual General Meeting
Sanjivani Paranteral shareholders approved the issuance of 5,00,000 convertible warrants to promoters on a preferential basis. A material related party transaction with subsidiary SPL Infusion was also cleared.
Sanjivani Paranteral Results Update
Sanjivani Paranteral reported Q1 FY27 results, with total income of ₹23.99 Crore and a net profit of ₹2.49 Crore. The company demonstrated strong year-on-year growth across key metrics.
Sanjivani Paranteral Investor Presentation: Key Takeaways
Sanjivani Paranteral Q1 FY27 consolidated revenue grew 33.8% YoY to ₹238.4 Mn, driven by the new Pune IV-fluid plant ramp-up. Transitioning to a multi-vertical platform with injectables, orals, and nutraceuticals.
- Call
- Guides 110% growth